Sign In
Buy NCNA
$2.03
-0.0400 (-1.93%)
At Close: Jun 03, 2026
NuCana Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update
04:01pm, Wednesday, 20'th Mar 2024
Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety
Why Is NuCana (NCNA) Stock Up 102% Today?
07:52am, Wednesday, 13'th Mar 2024
NuCana (NASDAQ: NCNA ) stock is rising on Wednesday as the clinical-stage biopharmaceutical company's shares experience heavy trading this morning. That has more than 9.6 million shares of the compan
NuCana to Present at TD Cowen's 44th Annual Health Care Conference
08:00am, Tuesday, 27'th Feb 2024
EDINBURGH, United Kingdom, Feb. 27, 2024 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present
NuCana: Potential Turnaround In 2024 But Risky
02:39am, Wednesday, 03'rd Jan 2024
NCNA is a beaten-down stock for numerous reasons, including failure of its prior lead candidate (Acelarin) in two phase 3 trials, as well as a limited cash runway. However, there are good reasons to b
NuCana Reports Third Quarter 2023 Financial Results and Provides Business Update
04:01pm, Thursday, 16'th Nov 2023
Announced Encouraging Updates from NUC-3373 and NUC-7738 Demonstrating Promising Efficacy and Safety Data
NuCana Announces Listing Transfer to Nasdaq Capital Market
04:01pm, Friday, 10'th Nov 2023
EDINBURGH, United Kingdom, Nov. 10, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) announced today that it has received approval from Listing Qualifications Dep
NuCana to Present at the Jefferies London Healthcare Conference
04:01pm, Wednesday, 08'th Nov 2023
EDINBURGH, United Kingdom, Nov. 08, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present
NuCana to Participate in the Truist Securities 2023 BioPharma Symposium
04:01pm, Wednesday, 01'st Nov 2023
EDINBURGH, United Kingdom, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (Nasdaq: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will host on
Data from the NuTide:701 Study Indicate NUC-7738 May Potentiate the Activity of Anti-PD-1 Agents in Patients who were Refractory to or Progressed on Prior Immunotherapy, including Anti-PD-1 Therapy
NUC-3373 Demonstrates Promising Anti-Tumor Activity and a Favorable Safety Profile as part of NUFIRI-bevacizumab and NUFOX-bevacizumab in Second-line Colorectal Cancer Patients
Why Is NuCana (NCNA) Stock Down Today?
08:46am, Tuesday, 10'th Oct 2023
NuCana (NASDAQ: NCNA ) stock is sliding lower on Tuesday as the clinical-stage biopharmaceutical company prepares for a presentation this week. NuCana is set to attend the AACR-NCI-EORTC Internationa
Bears are Losing Control Over NuCana PLC Sponsored ADR (NCNA), Here's Why It's a 'Buy' Now
11:17am, Thursday, 28'th Sep 2023
NuCana PLC Sponsored ADR (NCNA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions
NuCana Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023
08:00am, Monday, 18'th Sep 2023
EDINBURGH, United Kingdom, Sept. 18, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced four presentations at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Ca
NuCana Reports Second Quarter 2023 Financial Results and Provides Business Update
04:01pm, Wednesday, 16'th Aug 2023
On Track to Present Data Updates from All Ongoing Clinical Studies in the Second Half of 2023
NuCana to Present at the Jefferies Healthcare Conference
08:00am, Thursday, 01'st Jun 2023
EDINBURGH, United Kingdom, June 01, 2023 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will present
